Analyst Increases Delcath Systems Price Target to $29 After Q4 Revenue of $20.7M
An analyst raised Delcath Systems' price target to $29 from $28 while maintaining a Buy rating following preliminary Q4 results. The company reported preliminary Q4 revenue of $20.7 million and full-year 2025 revenue of $85.2 million, led by Hepzato sales totaling $19.0 million for the quarter and $78.8 million for the year.
1. Price Target Increase
An analyst raised Delcath Systems' price target to $29 from $28 while maintaining a Buy rating, reflecting confidence in the company’s interventional oncology portfolio.
2. Preliminary Q4 and Full-Year Results
Delcath reported preliminary Q4 revenue of $20.7 million and full-year 2025 revenue of $85.2 million, driven primarily by Hepzato sales of $19.0 million for the quarter and $78.8 million for the year, with the remainder attributed to Chemosat.
3. Hepzato Contribution and Cash Flow
Hepzato has emerged as a steadier revenue contributor, generating strong operating cash flow and minimal leverage, which enables Delcath to internally fund clinical programs and support its share repurchase plan.
4. Clinical Expansion and Share Repurchase
Robust free cash flow positions the company to expand Hepzato into additional indications and underpins the execution of its previously announced $25 million share repurchase program.